![Hani N. Sabbah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Hani N.
Sabbah is the founder of G3 Pharmaceuticals, Inc. He is currently working as a Director at MateraCor, Inc.
Hani N. Sabbah active positions
Companies | Position | Start |
---|---|---|
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Director/Board Member | - |
Former positions of Hani N. Sabbah
Companies | Position | End |
---|---|---|
G3 Pharmaceuticals, Inc.
![]() G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
G3 Pharmaceuticals, Inc.
![]() G3 Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology G3 Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. It manufactures and develops galectin-3 biology, cardiovascular pharmaceutical and carbohydrate drugs. The company is headquartered in Lexington, MA. | Health Technology |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | Health Technology |
- Stock Market
- Insiders
- Hani N. Sabbah